Manufacturer of Controlled Substances; Notice of Registration, 17260-17261 [05-6701]
Download as PDF
<![CDATA[
17260
Federal Register / Vol. 70, No. 64 / Tuesday, April 5, 2005 / Notices
Lakeview Interagency Office, 1301
South G Street, Lakeview, OR 97630,
(541) 947–6107, or ptalbott@or.blm.gov
and/or from the following Web site
https://www.or.blm.gov/SEOR-RAC.
Dated: March 30, 2005.
Shirley Gammon,
Manager, Lakeview District.
[FR Doc. 05–6677 Filed 4–4–05; 8:45 am]
Bureau of Land Management
[CO–922–05–1310–FI; COC63406]
Notice of Proposed Reinstatement of
Terminated Oil and Gas Lease
COC63406
Bureau of Land Management;
Interior.
Notice of proposed
reinstatement of terminated oil and gas
lease.
ACTION:
SUMMARY: Pursuant to the provisions of
30 U.S.C. 188(d) and (e), and 43 CFR
3108.2–3(a) and (b)(1), a petition for
reinstatement of oil and gas lease
COC63406 for lands in Delta County,
Colorado, was timely filed and was
accompanied by all the required rentals
accruing from the date of termination.
FOR FURTHER INFORMATION CONTACT:
Bureau of Land Management, Beverly A.
Derringer, Chief, Fluid Minerals
Adjudication, at 303–239–3765.
The lessee
has agreed to the amended lease terms
for rentals and royalties at rates of $5.00
per acre, or fraction thereof, per year
and 162⁄3 percent, respectively. The
lessee has paid the required $500
administrative fee and $155 to
reimburse the Department for the cost of
this Federal Register notice. The lessee
has met all the requirements for
reinstatement of the lease as set out in
Section 31 (d) and (e) of the Mineral
Lands Leasing Act of 1920 (30 U.S.C.
188), and the Bureau of Land
Management is proposing to reinstate
lease COC63406 effective August 1,
2004, subject to the original terms and
conditions of the lease and the
increased rental and royalty rates cited
above.
Dated: February 8, 2005.
Beverly A. Derringer,
Chief, Fluid Minerals Adjudication.
[FR Doc. 05–6691 Filed 4–4–05; 8:45 am]
BILLING CODE 4310–JB–M≤
VerDate jul<14>2003
19:48 Apr 04, 2005
Jkt 205001
Prospective Grant of Exclusive Patent
License
Bureau of Reclamation,
Interior.
ACTION: Notice.
DEPARTMENT OF THE INTERIOR
SUPPLEMENTARY INFORMATION:
Bureau of Reclamation
AGENCY:
BILLING CODE 4310–33–P
AGENCY:
DEPARTMENT OF THE INTERIOR
SUMMARY: This notice is issued in
accordance with 35 U.S.C. 209(c)(1) and
37 CFR 404.7(a)(1)(I). The Bureau of
Reclamation (Reclamation) is
contemplating the granting of an
exclusive license in the United States to
practice the invention embodied in U.S.
Patent No. 6,466,009 B1, entitled,
‘‘Flexible Printed Circuit Magnetic Flux
Probe.’’ The exclusive license is to be
granted to Iris Power Engineering
having a place of business in Toronto,
Canada. Iris Power Engineering is
owned by Koch Industries, Inc. of
Wichita, Kansas. The patent rights in
this invention have been assigned to the
United States of America.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. While the
primary purpose of this notice is to
announce Reclamation’s intent to grant
an exclusive license to practice the
above listed patent, it also serves to
publish the availability of this patent for
licensing in accordance with law. The
prospective license may be granted
unless Reclamation receives written
evidence and argument which establish
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
DATES: Written evidence and arguments
against granting the prospective license
must be received by fifteen (15) days
from the date of this notice.
ADDRESSES: Inquiries, comments, and
other materials relating to the
contemplated license may be submitted
to Chuck Hennig, Research Coordinator,
Bureau of Reclamation, Office of the
Research Director, D–9000, P.O. Box
25007, Denver, CO 80225–0007.
A copy of the above identified patent
may be purchased from the U.S. Patent
and Trademark Office, by calling (703)
308–9726 or (800) 972–6382 or
downloaded free of charge from the U.S.
Patent and Trademark Office Web site at
https://www.uspto.gov.
FOR FURTHER INFORMATION CONTACT:
Chuck Hennig (chennig@do.usbr.gov),
Research Coordinator, at 303–445–2134
or Siegie Potthoff
(spotthoff@do.usbr.gov), Program
Administrator, at 303–445–2136.
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
The
invention relates to a flexible magnetic
flux probe useful in the field of rotary
generator and motor condition
monitoring. Additional R&D is required
to develop a commercially viable
version of the device. In addition, a
significant investment must be made to
develop a market niche for the device.
Competing applications completed
and received by Reclamation in
response to this notice within fifteen
(15) days of this posting will be
considered as objections to the grant of
the contemplated license. Application
forms are available from the Office of
the Research Director, Bureau of
Reclamation at the address above.
Reclamation’s practice is to make
comments, including names and home
addresses of respondents, available for
public review. Individual respondents
may request that we withhold their
home address from public disclosure,
which we will honor to the extent
allowable by law. There may be
circumstances in which we would
withhold a respondent’s identity from
public disclosure, as allowable by law.
If you wish us to withhold your name
and/or address, you must state this
prominently at the beginning of your
comment. We will make all submissions
from organizations or businesses, and
from individuals identifying themselves
as representatives or officials of
organizations or businesses, available
for public disclosure in their entirety.
SUPPLEMENTARY INFORMATION:
Dated: March 2, 2005.
Charles Hennig,
Research Coordinator, Denver Office.
[FR Doc. 05–6711 Filed 4–4–05; 8:45 am]
BILLING CODE 4310–MN–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005, (70 FR 388–389),
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by renewal and on October
13, 2004 by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedule II:
Drug
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Dextropropoxyphene (9273) .........
E:\FR\FM\05APN1.SGM
05APN1
Schedule
II
II
II
17261
Federal Register / Vol. 70, No. 64 / Tuesday, April 5, 2005 / Notices
Drug
Schedule
Fentanyl (9801) ............................
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6701 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005, (70 FR 391), EliElsohly Laboratories, Inc., Mahmoud A.
Elsohly PhD., 5 Industrial Park Drive,
Oxford, Mississippi 38655, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Thebaine (9333), a basic class of
controlled substance listed in Schedule
II.
The company plans to manufacture
the listed controlled substance in bulk
for use in analysis and drug test
standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of EliElsohly Laboratories, Inc. to
manufacture the listed basic class of
controlled substance is consistent with
VerDate jul<14>2003
19:48 Apr 04, 2005
Jkt 205001
the public interest at this time. DEA has
investigated Eli-Elsohly Laboratories,
Inc., to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6699 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importation of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(1)), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(b) authorizing the importation
of such substances, provide
manufacturers holding registrations for
the bulk manufacture of the substances
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on May 20,
1998, Ethical Nutritional, LLC, 176
University Parkway, Pomona, California
91768–4300, made application to the
Drug Enforcement Administration
(DEA) for registration as an importer of
Coca Leaves (9040), a basic class of
controlled substances listed in Schedule
II.
The company plans to import small
quantities of the listed controlled
substance to manufacture homeopathic
medications for human consumption.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file written
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 5, 2005.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import the basic classes
of controlled substances listed in
Schedules I or II are and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6700 Filed 4–4–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005, (70 FR 391), Houba,
Inc., P.O. Box 190, 16235 State Road 17,
Culver, Indiana 46511, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedule II; and by
letter dated October 1, 2004, to modify
its name to Acura Pharmaceutical
Technologies, Inc., and change the
address by removing the P.O. Box 190.
Drug
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
E:\FR\FM\05APN1.SGM
05APN1
]]>Agencies
[Federal Register Volume 70, Number 64 (Tuesday, April 5, 2005)]
[Notices]
[Pages 17260-17261]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6701]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated December 21, 2004, and published in the Federal
Register on January 4, 2005, (70 FR 388-389), Cambrex Charles City,
Inc., 1205 11th Street, Charles City, Iowa 50616, made application by
renewal and on October 13, 2004 by letter to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in Schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Dextropropoxyphene (9273).................. II
[[Page 17261]]
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Cambrex Charles City, Inc. to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Cambrex Charles City, Inc. to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33(a), the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-6701 Filed 4-4-05; 8:45 am]
BILLING CODE 4410-09-P
